Cargando…
Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)
BACKGROUND: Data on the prevalence of dyslipidemia and attainment of goal/normal lipid levels in a Swedish population are scarce. The objective of this study is to estimate the prevalence of dyslipidemia and attainment of goal/normal lipid levels in patients treated with lipid modifying therapy (LMT...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3009647/ https://www.ncbi.nlm.nih.gov/pubmed/21114824 http://dx.doi.org/10.1186/1471-2458-10-737 |
_version_ | 1782194720788709376 |
---|---|
author | Pettersson, Billie Ambegaonkar, Baishali Sazonov, Vasilisa Martinell, Mats Stålhammar, Jan Wändell, Per |
author_facet | Pettersson, Billie Ambegaonkar, Baishali Sazonov, Vasilisa Martinell, Mats Stålhammar, Jan Wändell, Per |
author_sort | Pettersson, Billie |
collection | PubMed |
description | BACKGROUND: Data on the prevalence of dyslipidemia and attainment of goal/normal lipid levels in a Swedish population are scarce. The objective of this study is to estimate the prevalence of dyslipidemia and attainment of goal/normal lipid levels in patients treated with lipid modifying therapy (LMT). METHODS: This longitudinal retrospective observational study covers time periods before and after treatment. Data were collected from 1994-2007 electronic patient records in public primary healthcare centers in Uppsala County, Sweden. Patients were included if they had been treated with LMT and had at least one lipid abnormality indicating dyslipidemia and if complete lipid profile data were available. Thresholds levels for lipids were defined as per Swedish guidelines. RESULTS: Among 5,424 patients included, at baseline, the prevalence of dyslipidemia (≥1 lipid abnormality) was by definition 100%, while this figure was 82% at follow-up. At baseline, 60% had elevated low-density lipoprotein (LDL-C) combined with low high-density lipoprotein (HDL-C) and/or elevated triglycerides (TG s), corresponding figure at follow-up was 36%. Low HDL-C and/or elevated TGs at follow-up remained at 69% for patients with type 2 diabetes mellitus (T2DM), 50% among patients with coronary heart disease (CHD) and 66% among patients with 10 year CHD risk >20%. Of the total sample, 40% attained goal levels of LDL-C and 18% attained goal/normal levels on all three lipid parameters. CONCLUSIONS: Focusing therapy on LDL-C reduction allows 40% of patients to achieve LDL-C goal and helps reducing triglyceride levels. Almost 60% of patients experience persistent HDL-C and/or triglyceride abnormality independently of LDL-C levels and could be candidates for additional treatments. |
format | Text |
id | pubmed-3009647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30096472010-12-24 Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA) Pettersson, Billie Ambegaonkar, Baishali Sazonov, Vasilisa Martinell, Mats Stålhammar, Jan Wändell, Per BMC Public Health Research Article BACKGROUND: Data on the prevalence of dyslipidemia and attainment of goal/normal lipid levels in a Swedish population are scarce. The objective of this study is to estimate the prevalence of dyslipidemia and attainment of goal/normal lipid levels in patients treated with lipid modifying therapy (LMT). METHODS: This longitudinal retrospective observational study covers time periods before and after treatment. Data were collected from 1994-2007 electronic patient records in public primary healthcare centers in Uppsala County, Sweden. Patients were included if they had been treated with LMT and had at least one lipid abnormality indicating dyslipidemia and if complete lipid profile data were available. Thresholds levels for lipids were defined as per Swedish guidelines. RESULTS: Among 5,424 patients included, at baseline, the prevalence of dyslipidemia (≥1 lipid abnormality) was by definition 100%, while this figure was 82% at follow-up. At baseline, 60% had elevated low-density lipoprotein (LDL-C) combined with low high-density lipoprotein (HDL-C) and/or elevated triglycerides (TG s), corresponding figure at follow-up was 36%. Low HDL-C and/or elevated TGs at follow-up remained at 69% for patients with type 2 diabetes mellitus (T2DM), 50% among patients with coronary heart disease (CHD) and 66% among patients with 10 year CHD risk >20%. Of the total sample, 40% attained goal levels of LDL-C and 18% attained goal/normal levels on all three lipid parameters. CONCLUSIONS: Focusing therapy on LDL-C reduction allows 40% of patients to achieve LDL-C goal and helps reducing triglyceride levels. Almost 60% of patients experience persistent HDL-C and/or triglyceride abnormality independently of LDL-C levels and could be candidates for additional treatments. BioMed Central 2010-11-29 /pmc/articles/PMC3009647/ /pubmed/21114824 http://dx.doi.org/10.1186/1471-2458-10-737 Text en Copyright ©2010 Pettersson et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Pettersson, Billie Ambegaonkar, Baishali Sazonov, Vasilisa Martinell, Mats Stålhammar, Jan Wändell, Per Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA) |
title | Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA) |
title_full | Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA) |
title_fullStr | Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA) |
title_full_unstemmed | Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA) |
title_short | Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA) |
title_sort | prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among swedish patients with dyslipidemia (primula) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3009647/ https://www.ncbi.nlm.nih.gov/pubmed/21114824 http://dx.doi.org/10.1186/1471-2458-10-737 |
work_keys_str_mv | AT petterssonbillie prevalenceoflipidabnormalitiesbeforeandafterintroductionoflipidmodifyingtherapyamongswedishpatientswithdyslipidemiaprimula AT ambegaonkarbaishali prevalenceoflipidabnormalitiesbeforeandafterintroductionoflipidmodifyingtherapyamongswedishpatientswithdyslipidemiaprimula AT sazonovvasilisa prevalenceoflipidabnormalitiesbeforeandafterintroductionoflipidmodifyingtherapyamongswedishpatientswithdyslipidemiaprimula AT martinellmats prevalenceoflipidabnormalitiesbeforeandafterintroductionoflipidmodifyingtherapyamongswedishpatientswithdyslipidemiaprimula AT stalhammarjan prevalenceoflipidabnormalitiesbeforeandafterintroductionoflipidmodifyingtherapyamongswedishpatientswithdyslipidemiaprimula AT wandellper prevalenceoflipidabnormalitiesbeforeandafterintroductionoflipidmodifyingtherapyamongswedishpatientswithdyslipidemiaprimula |